Back

SPI-62-CL-2001

Official Title

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Study Details

The purpose of this study is to find out about the safety and efficacy of an experimental drug for the possible treatment of Cushing's syndrome.

Principal Investigator

Dr. Julie Silverstein

IRB Number

202203156

Eligibility

1. Participants must have documented diagnosis of ACTH-dependent Cushings's syndrome
2. Participants must be age 18 or older

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back